A Study Evaluating the Effectiveness and Safety of Pulsed Field Ablation Using the FARAPULSE™ System for Electrical Isolation of Pulmonary Veins and Superior Vena Cava
Sponsored by Shanghai Zhongshan Hospital
About this trial
Last updated 9 months ago
Study ID
Status
Type
Phase
Placebo
Accepting
Trial Timing
Started 8 months ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
* Age between 18 and 75 years.
* Documented diagnosis of paroxysmal atrial fibrillation (PAF), defined as typical AF electrographic characteristics (absence of P waves with irregular fibrillatory waves) recorded on 12-lead ECG or symptomatic Holter monitoring, with each episode lasting less than 7 days.
* Symptomatic despite attempted antiarrhythmic drug therapy.
* Scheduled to undergo initial catheter ablation procedure.
* Voluntarily provided written informed consent.
Exclusion Criteria
* AF secondary to electrolyte imbalance, thyroid disorders, or other reversible/non-cardiac causes.
* Persistent atrial fibrillation.
* Presence of persistent left superior vena cava.
* Contraindications to pulsed field ablation (e.g., left atrial appendage thrombus, post-atrial septal defect device closure, permanent metallic implants in the left atrium) or contraindications to anticoagulant therapy.
* Unsuitable for deep sedation/anesthesia per operator assessment.
* Life expectancy less than 1 year.
* Other conditions deemed inappropriate for inclusion by the investigator.
